ERBB2 and lung carcinoma: Similarly, STX-478 and alpelisib treatment provided comparable tumor growth control in NCI-H1048 lung carcinoma, which contains a double (H1047R/K411R) PI3Kα mutation, as well as in the HCC1954 HR+HER2+ breast cancer model (Fig. 5A).